Tech Center 1700 • Art Units: 1641 1642 1644 1684 1759
This examiner grants 57% of resolved cases
Sharon X. Wen manages a large volume of 633 resolved cases in Art Unit 1641. The allowance rate is 56.9 percent, and the median days to allowance is 1371. These figures reflect the rigorous examination standards and long timelines typical of Tech Center 1600. Practitioners should be prepared for a prosecution cycle that lasts 1371 days and involves significant examiner scrutiny.
The interview lift of 32.6 percent is a key metric for applicants. It shows that interviews significantly enhance the 56.9 percent baseline allowance rate. Given the high case volume of 633 and the pendency of 1371 days, an interview is a recommended tactic to resolve issues and move toward a grant more effectively. The 32.6 percent lift suggests that the examiner is open to discussing technical nuances that may not be fully captured in written responses. By leveraging this lift, practitioners can improve their odds of success in a challenging docket. The examiner's extensive history provides a reliable basis for this proactive strategy, emphasizing the value of direct communication in Art Unit 1641 across the 633 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18286955 | Glycan Targets of Serum IgG and IgM Antibodies | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17185469 | METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER | Non-Final OA | SANOFI |
| 18416231 | COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | Final Rejection | Mallinckrodt Pharmaceuticals Ireland Limited |
| 17780407 | COMPOSITIONS AND METHODS FOR EPITOPE SCANNING | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 16348653 | COMBINED THERAPIES FOR ATHEROSCLEROSIS, INCLUDING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | Non-Final OA | Amgen Inc. |
| 13931716 | METHODS FOR TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS | Final Rejection | AMGEN INC. |
| 18589200 | DOSE | Non-Final OA | AstraZeneca AB |
| 18262843 | ADJUVANT THERAPY FOR CANCER | Final Rejection | Iovance Biotherapeutics, Inc. |
| 18559910 | MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE | Non-Final OA | MedImmune, LLC |
| 18559195 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS | Non-Final OA | Viela Bio, Inc |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy